Combined double CK5/P63 stain: Useful adjunct test for diagnosing pulmonary squamous cell carcinoma
暂无分享,去创建一个
[1] Masahiro Tsuboi,et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] A. Calvo,et al. Improving the accuracy of FNA lung biopsies in a community hospital. , 2010 .
[3] V. Rusch,et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] H. Benjamin,et al. Accurate Classification of Non–Small Cell Lung Carcinoma Using a Novel MicroRNA-Based Approach , 2010, Clinical Cancer Research.
[5] J. Austin,et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification , 2009 .
[6] D. Ross,et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma , 2009, Modern Pathology.
[7] G. Scagliotti,et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung , 2009, Modern Pathology.
[8] C. D. Savci-Heijink,et al. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. , 2009, The American journal of pathology.
[9] Gideon Rechavi,et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Bo Jian,et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens , 2009, Diagnostic cytopathology.
[11] G. Scagliotti,et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.
[12] Anna Spreafico,et al. The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] N. Sunaga,et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer , 2008, British Journal of Cancer.
[15] Richard Pazdur,et al. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. , 2007, The oncologist.
[16] Tammy F. Glenn,et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration , 2007, International journal of cancer.
[17] M. Paesmans,et al. Bevacizumab for non-small-cell lung cancer. , 2007, The New England journal of medicine.
[18] D. Goldenberg,et al. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers , 2007, BMC Cancer.
[19] D. Burstein,et al. Cytology applications of p63 and TTF‐1 immunostaining in differential diagnosis of lung cancers , 2005, Diagnostic cytopathology.
[20] N. Kohno,et al. Polymorphism of the MUC1 mucin gene is associated with susceptibility to lung adenocarcinoma and poor prognosis. , 2005, Oncology reports.
[21] D. Burstein,et al. p63 immunostaining in destained bronchoscopic cytological specimens , 2005, Diagnostic cytopathology.
[22] D. Burstein,et al. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. , 2003, American journal of clinical pathology.
[23] D. Burstein,et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. , 2002, Human pathology.
[24] U. Pastorino,et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? , 2002, The Journal of pathology.
[25] R. Strausberg,et al. A preliminary transcriptome map of non-small cell lung cancer. , 2002, Cancer research.
[26] M Dietel,et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. , 2001, American journal of clinical pathology.
[27] W. Kaelin,et al. p53 family update: p73 and p63 develop their own identities. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[28] A. Leong,et al. Manual of Diagnostic Antibodies for Immunohistology , 1998 .
[29] D. Zander,et al. Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach , 2005, Modern Pathology.